Search by

Emergent Bioservices

Company Headquarters

400 Professional Drive , Suite 400, Gaithersburg, MD, 20879, US

Driving Directions Phone: View Phone

Request more information from Emergent Bioservices

White Papers / Tech Papers

Finding the Right CDMO Partner for Tech Transfer

Avoid Risks and Delays in Bringing your Drug to Market

Released By Emergent Bioservices

News Releases

Emergent Secures Agreement with Providence Therapeutics for its mRNA COVID-19 Vaccine Candidate

Total baseline value for Emergent is approximately $90 million USD, further expanding the collaboration between the companies, which began in February 2021.

Released By Emergent Bioservices

Literature / Brochures

Emergent CDMO Capabilities – Perfecting Your Formula

For innovators taking on global health risks, rare diseases, or novel medicines, Emergent is an ideal integrated CDMO and a valued partner.

Released By Emergent Bioservices

News Releases

Humanigen & Emergent Biosolutions Announce Agreement for Phase 3 Covid-19 Therapeutic Candidate

Lenzilumab™ is currently in a Phase 3 clinical trial evaluating patients hospitalized with COVID-19. Humanigen intends to file for EUA first quarter of 2021.

Released By Emergent Bioservices

News Releases

Mount Sinai Health System, Emergent BioSolutions, and ImmunoTek Bio Centers Form Collaboration

to Develop Emergent’s COVID-19 Hyperimmune Globulin (COVID-HIG) Product Candidate with U.S. Department of Defense Funding

Released By Emergent Bioservices

News Releases

Emergent BioSolutions to Invest $75 Million

in Canton Site and Expand Viral Vector and Gene Therapy Capability

Released By Emergent Bioservices

News Releases

Emergent BioSolutions Joins U.S. Government’s Warp Speed Program

in Landmark Public-Private CDMO Partnership for COVID-19 Vaccine Development and Manufacturing

Released By Emergent Bioservices

News Releases

Emergent BioSolutions Signs Agreement to be U.S. Manufacturing Partner

for Johnson & Johnson’s Lead Vaccine Candidate for COVID-19

Released By Emergent Bioservices

News Releases

Emergent BioSolutions Signs Development and Manufacturing Agreement

with Vaxart for their Experimental Oral Vaccine Candidate for Coronavirus Disease

Released By Emergent Bioservices

News Releases

Emergent BioSolutions Signs Development and Manufacturing Agreement

With Novavax for Experimental Vaccine Candidate for Coronavirus Disease

Released By Emergent Bioservices

Related Content